Brain cancer patients get virus injection in new trial

NCT ID NCT06126744

First seen Sep 30, 2025 · Last updated Jun 15, 2026 · Updated 34 times

Summary

This early-stage study tests a modified herpes virus (MVR-C5252) injected directly into brain tumors in people with recurrent high-grade glioma. The main goals are to find a safe dose and see if the virus can shrink tumors or slow their growth. About 51 adults with tumors that returned after standard treatment will take part.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECURRENT HIGH-GRADE GLIOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Duke University

    RECRUITING

    Durham, North Carolina, 27750, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Memorial Sloan Kettering

    RECRUITING

    New York, New York, 10065, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

Conditions inferred from the trial description

These were inferred from the trial's summary, not listed by the trial registrant.